Stay updated with breaking news from Rewalk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
captain derek herrera, in the wheelchair. his 4-year-old twins watching. >> whoa! >> they watch as their father stands up for the first time, he does it in front of them. >> dad, you're tall! you're walking! >> yeah! >> hudson and hunter amazed. >> are you walking? >> i'm about to. what do you think? >> tall! >> we have followed captain herrera for years. leading his team 0 patrol in afghanistan, he was shot by a sniper in 2012. paralyzed from the chest down. afterward, the grueling recovery. the rehab. and that moment at bob woodruff's standup for heroes when captain herrera was about to walk across the stage with rewalk, exoskeleton technology. >> i forgot what walking was like. >> you're going to surprise the audience. >> yes. >> and he did it. this time, standing up before
Inside Politics With Abby Phillip-20210919-12:15:15 vimarsana.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vimarsana.com Daily Mail and Mail on Sunday newspapers.
jocelyn is not alone. this is raj, leaving intensive care. bye, raj. i could not stand, my foot would just drop. there wasn't strength. i could not stand after closing my eyes, everything, body would just shake. doing so well. and done. i never imagined i had to learn to rewalk. good. well done. covid left raj with long lasting problems. damage to the kidney, damage to the heart, neurological damage into my legs. i still have to walk with the walking stick. jocelyn and raj have become friends. they were on the same ward at epsom hospital in surrey. staff at the hospital quickly realised patients would need significant help with so—called long covid. there are now more than a million people in the uk, suffering from long—term aftereffects
learn to rewalk. good. well done. covid left raj _ learn to rewalk. good. well done. covid left raj with _ learn to rewalk. good. well done. covid left raj with long _ learn to rewalk. good. well done. covid left raj with long lasting - covid left raj with long lasting problems. damage to the kidney, damage to the heart, and neurological damage into my leg, i still have to walk with the walking stick. , , . . still have to walk with the walking stick. . , ., ., ., still have to walk with the walking stick. , , ., ., ., , stick. jocelyn and ra' have become friends, stick. jocelyn and ra' have become friends. they h stick. jocelyn and ra' have become friends, they on — stick. jocelyn and ra' have become friends, they on the — stick. jocelyn and raj have become friends, they on the same - stick. jocelyn and raj have become friends, they on the same ward - stick. jocelyn and raj have become friends, they on the same ward in | friends, they on the same ward in surrey. staff quickly realised patients would need enough scant help with so—called long covid. there are now more than a million people in the uk suffering long—term aftereffects of testify virus. i suffering long-term aftereffects of testify virus-— testify virus. i have seen it described _ testify virus. i have seen it described after _ testify virus. i have seen it described after as - testify virus. i have seen it described after as the - testify virus. i have seen it - described after as the pandemic after the pandemic. long covid is an barella term for after the pandemic. long covid is an ba rella term for lots after the pandemic. long covid is an barella term for lots of after the pandemic. long covid is an ba rella term for lots of different condition, ongoing fatigue, breathlessness, impact on mental health. problems with sleep, sometimes cardiac issues and range of different symptoms. an exercise class just part of the rehab programme run by the epsom and st helier hospital trust. to
whenjocelyn left hospital last year, she had no idea just how long it would take to recover. evenjust to talk was an effort for me. even just this time, i was really breathless, very short of breath, even at rest. i was so frail. i was so ill. i was so extremely vulnerable, really. jocelyn is not alone. this is raj leaving intensive care. i could not stand — my foot would just drop. there wasn't strength. i could not stand. after closing my eyes, everything — body would just shake. doing so well. and done. i never imagined i had to learn to re—walk. yeah. oh, good, well done. covid left raj with long—lasting problems. damage to the kidney, damage to the heart and neurological damage into my legs. i still have to walk
Detailed text transcripts for TV channel - BBCNEWS - 20210621:09:39:15 archive.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from archive.org Daily Mail and Mail on Sunday newspapers.
very short of breath, even at rest. i was so frail, i was so ill. i was so extremely vulnerable, really. jocelyn is not alone. this is raj metkar leaving intensive care. i could not stand — my foot would just drop. there wasn't strength, i could not stand. after closing my eyes, everything, body would just shake. doing so well. and done. i never imagined i had to learn to re—walk. oh, good, well done. covid left raj with long—lasting problems. damage to the kidney, damage to the heart, and neurological damage into my legs. i still have to walk with the walking stick. jocelyn and raj have become friends. they were on the same ward at epsom hospital in surrey. staff at the hospital quickly realised patients would need significant help with so—called long covid.
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Feb. 19, 2021 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that it has entered into securities purchase agreements with certain institutional and other accredited investors to raise $40.0 million through the issuance of 10,921,502 ordinary shares and warrants to purchase up to 5,460,751 ordinary shares, at a purchase price of $3.6625 per share and associated warrant, in a private placement priced “at-the-market” under Nasdaq rules. The warrants will have a term of five and one-half years, be exercisable immediately following the issuance date and have an exercise price of $3.60 per ordinary share. H.C. Wainwright & Co., LLC acted as the sole placement agent for the offering. The Company intends to use the net proceeds for: (i) sales, marketing and reimbursement expenses related to market development activities of its ReStore and Personal 6.0 devices, broadening third-party payor and CMS coverage for its ReWalk Personal device, and commercializing its new product lines added through distribution agreements; (ii) research and development of its lightweight exo-suit technology for potential home personal health utilization for multiple indications and future generation designs for its spinal cord injury device; (iii) routine product updates; and (iv) general corporate purposes, including working capital needs. The closing of the private placement is expected to occur on or about February 23, 2021, subject to satisfaction of customary closing conditions. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company is required to file an initial registration statement with the Securities and Exchange Commission (the “SEC”) covering the resale of the ordinary shares to be issued to the investors (including the shares underlying the warrants) no later than 20 days after today and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 90 days after today in the event of a “full review” by the SEC. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. About ReWalk Robotics Ltd. ReWalk Robotics Ltd. develops, manufactures, and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel, and Germany. For more information on the ReWalk systems, please visit www.rewalk.com. ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the United States. ReStore® is a registered trademark of ReWalk Robotics Ltd. in Europe and an allowed trademark in the United States. Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements include, among others: the completion of the private placement; the satisfaction of customary closing conditions related to the private placement and the intended use of net proceeds from the private placement; the adverse effect that the COVID-19 pandemic has had and may continue to have on the Company’s business and results of operations; ReWalk's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; ReWalk's ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk's ability to maintain and grow its reputation and the market acceptance of its products; ReWalk's ability to achieve reimbursement from third-party payors for its products; ReWalk's limited operating history and its ability to leverage its sales, marketing and training infrastructure; ReWalk's expectations as to its clinical research program and clinical results; ReWalk's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; ReWalk's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; ReWalk's ability to repay its secured indebtedness; ReWalk's ability to improve its products and develop new products; ReWalk's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on ReWalk's ability to market and sell its products; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's expectations as to the results of, and the Food and Drug Administration's potential regulatory developments with respect to its mandatory 522 postmarket surveillance study; ReWalk's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; ReWalk's ability to establish a pathway to commercialize its products in China; the impact of substantial sales of the Company's shares by certain shareholders on the market price of the Company's ordinary shares; ReWalk's ability to use effectively the proceeds of its offerings of securities; the risk of substantial dilution resulting from the periodic issuances of ReWalk's ordinary shares; the impact of the market price of the Company's ordinary shares on the determination of whether it is a passive foreign investment company; market and other conditions; and other factors discussed under the heading "Risk
he did. maybe it wasn't true. the fact that trump spoke out gives the democrats cover. but obviously we are living and i think s.e. spoke to it well. we are living in a world where how do you deal with the allegations? what's the standard of proof, the proper level of outrage versus waiting for facts. >> caution. >> that's all getting played out and reworked in real time. it will continue to impact the democratic primary. there are other incidents that come up. 99% of the time they are more true than false. everybody running for office on both sides now will say, hang on. let's make sure it is not another jussie smollett situation. we may have to walk something back. rewalk it and rewalk it again. >> to be clear, claims of crimes being perpetrated on someone are certainly 99% accurate